Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Morbidity and Mortality Weekly Report

Volumn 63, Issue 37, 2011, Pages 822-825

  Tomczyk, Sara ^a,b   Bennett, Nancy M ^c,d   Stoecker, Charles ^e   Gierke, Ryan ^b   Moore, Matthew R ^b   Whitney, Cynthia G ^b   Hadler, Stephen ^b   Pilishvili, Tamara ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c Pneumococcal Work Group   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; PNEUMOCOCCUS VACCINE; VACCINE;

ADVISORY COMMITTEE; AGED; ARTICLE; HUMAN; IMMUNIZATION; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; UNITED STATES;

ADVISORY COMMITTEES; AGED; HUMANS; IMMUNIZATION SCHEDULE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; VACCINES, CONJUGATE;

EID: 84907454989     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bonten M, Bolkenbaas M, Huijts S, et al. Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Abstract no. 0541. Pneumonia 2014;3:95. Available at https://pneumonia.org.au/public/journals/22/ PublicFolder/ABSTRACTBOOKMASTERforwebupdated20-3-14.pdf.
2. Advisory Committee on Immunization Practices. GRADE tables: 2014. Atlanta, GA: US Department of Health and Human Services, CDC; 2014. Available at http://www.cdc.gov/vaccines/acip/recs/grade/pneumo-vac-adult.html.
3. Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Network. Unpublished data (2013). Atlanta, GA: US Department of Health and Human Services, CDC; 2013.
4. Grijalva C, Wunderink R, Williams D, et al. Distribution of pneumococccal serotypes detected through urine analysis among US adults hospitalized with pneumonia after introduction of PCV13. Proceedings of the International Symposium on Pneumococci and Pneumococcal Diseases 2014; Hyderabad, India. Available at http://www2.kenes.com/isppd2014/ scientific/documents/isppd-9%20abstract%20book.pdf.
5. Food and Drug Administration. FDA expands use of Prevnar 13 vaccine for people ages 50 and older. Silver Spring, MD: US Department of Health and Human Services; Food and Drug Administration; 2011. Available at http:// www.fda.gov/newsevents/newsroom/pressannouncements/ucm285431.htm.
6. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61:816-9.
7. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31:3577-84.
8. Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013;31:3585-93.
9. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014;32:2364-74.
10. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013;31:3594-602.
11. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49:1318-25.
12. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska Native adults 55-70 years of age. Clin Infect Dis 2009;49:241-8.
13. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services; Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/bloodvaccinesandotherbiologics/ vaccinesandrelatedbiologicalproductsadvisorycommittee/ ucm279680.pdf.
14. Stoecker C. Incremental cost-effectiveness of modifying PPSV and PCV recommendations for adults age 50 and over. Presented at the Advisory Committee on Immunization Practices June 25, 2014 meeting, Atlanta, GA; 2014. Available at http://www.cdc.gov/vaccines/acip/meetings/ downloads/slides-2014-06/pcv13-02-stoecker.pdf.
15. CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010;59:1102-6.
16. Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011;29:5195-202.